Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

Company Overview

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$14.38 to C$14.91
• 50-Day Range: C$12.71 to C$17.89
• 52-Week Range: C$5.35 to C$19.69
• Volume: 21,882 shs
• Average Volume: 47,825 shs
• Market Capitalization: C$375.92 million
• P/E Ratio: 11.75
• Dividend Yield: N/A
• Price Target: C$12.50
• Consensus Rating: Buy

Cipher Pharmaceuticals Stock Analysis - MarketRank™

Cipher Pharmaceuticals scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cipher Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cipher Pharmaceuticals is 11.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cipher Pharmaceuticals is 11.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.13.

Price to Book Value per Share Ratio

Cipher Pharmaceuticals has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cipher Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cipher Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CPH.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 6 people have searched for CPH on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.38% of the stock of Cipher Pharmaceuticals is held by institutions.

CPH Stock Analysis - Frequently Asked Questions

How have CPH shares performed this year?

Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of the year. Since then, CPH shares have increased by 165.2% and is now trading at C$14.69.
View the best growth stocks for 2024 here.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (TSE:CPH) announced its quarterly earnings results on Thursday, November, 7th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The firm earned $14.15 million during the quarter, compared to analysts' expectations of $13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a trailing twelve-month return on equity of 28.43%.

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Cipher Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:CPH
• Previous Symbol: TSE:DND
• CUSIP: N/A
• CIK: N/A
• Web: www.cipherpharma.com
• Phone: +1-905-6025840
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$12.50
• High Stock Price Target: C$17.00
• Low Stock Price Target: C$8.00
• Potential Upside/Downside: -14.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C$1.25
• Trailing P/E Ratio: 11.75
• Forward P/E Ratio: 11.38
• P/E Growth: N/A
• Net Income: C$22.60 million
• Net Margins: 102.01%
• Pretax Margin: N/A
• Return on Equity: 28.43%
• Return on Assets: 7.90%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 11.18
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: C$22.16 million
• Price / Sales: 16.96
• Cash Flow: C$4.16 per share
• Price / Cash Flow: 3.53
• Book Value: C$3.68 per share
• Price / Book: 3.99

Miscellaneous

• Outstanding Shares: 25,590,000
• Free Float: N/A
• Market Cap: C$375.92 million
• Optionable: Not Optionable
• Beta: 1.20